Cambridge Trust’s C4 Therapeutics CCCC Stock Holding History

Cambridge Trust’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100	Closed	-$3K	–	954
2021 Q4	$3K	Buy	+100	New	+$3.96K	﹤0.01%	928

Other funds holding CCCC

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Cambridge Trust's CCCC Position: Q1 2022 in Review

Cambridge Trust sold out of C4 Therapeutics (CCCC) in Q1 2022, closing a stake of 100 shares — an estimated $3K sold.

Cambridge Trust first reported a position in CCCC in Q4 2021 and held it in 1 quarter. The position peaked at $3K in Q4 2021. 125 funds tracked by Wall St. Rank hold CCCC as of Q1 2022.

Cambridge Trust reported no remaining C4 Therapeutics position as of Q1 2022 after selling out during the quarter.
Cambridge Trust sold 100 C4 Therapeutics shares in Q1 2022, an estimated $3K.
Cambridge Trust first reported a position in C4 Therapeutics in Q4 2021 and held it in 1 quarter.
Cambridge Trust's C4 Therapeutics position peaked at $3K in Q4 2021.
125 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2022.

Based on Cambridge Trust's 13F filing for Q1 2022, filed 12 May 2022.